Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal

Fezolinetant is a neurokinin 3 receptor antagonist under investigation for treatment of menopausal symptoms. In a recent study, Lederman and colleagues(1) reported the safety and efficacy of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.

Detalles Bibliográficos
Autores principales: Gompel, Anne, Stuenkel, Cynthia A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313926/
https://www.ncbi.nlm.nih.gov/pubmed/37343519
http://dx.doi.org/10.1016/j.xcrm.2023.101076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313926/
https://www.ncbi.nlm.nih.gov/pubmed/37343519
http://dx.doi.org/10.1016/j.xcrm.2023.101076

Ejemplares similares